Relationship Between Serum CCL20,β2-MG and Postoperative Recurrence,Metastasis,Prognosis in Patients with Breast Cancer
Objective To analyze the relationship between serum C-C chemokine ligand 20(CCL20),β2-microglobulin(β2-MG)and postoperative recurrence,metastasis,prognosis in patients with breast cancer.Methods A total of 70 patients with breast cancer were enrolled as the study objects.According to presence or absence of recurrence within 3 years after surgery,they were divided into recurrence group(n =22)and non-recurrence group(n =48).The clinical data of patients were collected.The level of serum CCL20 was detected by enzyme-linked immunosorbent assay.The level of serum β2-MG was detected by full-auto-matic protein analyzer.The influencing factors of postoperative recurrence and metastasis in breast cancer patients were explored by logistic regression analysis.The survival curves were drawn by Kaplan-Meier method.The relationship between CCL20,β2-MG levels and survival time was analyzed.Results The differences in TNM staging,tumor size,estrogen receptor(ER),progesterone receptor(PR)and serum CCL20 and β2-MG levels between the 2 groups were statistically significant(P<0.05).The results of logistic regression analysis showed that ER positive,PR positive and high levels of serum CCL20 and β2-MG were risk factors of postoperative recurrence and metastasis in breast cancer patients(P<0.05).Survival analysis showed that3-year overall survival rate in patients with low-expression CCL20 was significantly higher than that with high-expression CCL20(71.43%vs 45.71%,Log-rank χ2 =4.769,P =0.029),and which in patients with low-expression β2-MG was significantly higher than that with high-expression β2-MG(77.14%vs 40.00%,Log-rank χ2 =8.910,P =0.003).Conclusion The changes of serum CCL20 and β2-MG can affect postoperative recurrence and metastasis in patients with breast cancer.The overall survival rate significantly decrea-ses in patients with high expressions of CCL20 and β2-MG.
Breast cancerC-C chemokine ligand 20β2-microglobulinRecurrence and metastasisSurvival time
万方数据
